Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma

Neuro-Oncology

Volumn 11, Issue 5, 2009, Pages 503-513

  Jahnke, Kristoph ^a   Muldoon, Leslie L ^b,c   Varallyay, Csanad G ^d   Lewin, Seth J ^b   Brown, Robert D ^b   Kraemer, Dale F ^b,c,e   Soussain, Carole ^f   Neuwelt, Edward A ^a,c,g  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e OREGON STATE UNIVERSITY   (United States)

^f CENTRE RENÉ HUGUENIN   (France)

^g PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Central nervous system lymphoma; Methotrexate; MRI; Rat model; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; GADOLINIUM; METHOTREXATE; RITUXIMAB; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LYMPHOMA; CANCER CELL CULTURE; CELL STRAIN MC116; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE RAT; RAT; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; IMAGE ENHANCEMENT; LYMPHOMA, B-CELL; MAGNETIC RESONANCE IMAGING; METHOTREXATE; RATS; RATS, NUDE; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349624594     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-119     Document Type: Article

References (43)

1. Eby NL, Grufferman S, Flannelly CM, Schold SC Jr, Vogel FS, Burger PC. Increasing incidence of primary brain lymphoma in the US. Cancer. 1988;62:2461-2465. (Pubitemid 18270106)
2. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23:9-17.
3. Batchelor t, Carson K, O'Neill A, et al. treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21:1044-1049.
4. Herrlinger U, Kuker W, Uhl M, et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol. 2005;57:843-847. (Pubitemid 40798622)
5. Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21:4489-4495. (Pubitemid 46594018)
6. Kraemer DF, Fortin D, Doolittle ND, Neuwelt EA. Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival. Neurosurgery. 2001;48:1033-1040. (Pubitemid 32336597)
7. Neuwelt EA. Mechanisms of disease: the blood-brain barrier. Neurosurgery. 2004;54:131-140.
8. Neuwelt EA, Goldman DL, Dahlborg SA, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol. 1991;9:1580-1590.
9. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998;16:859-863. (Pubitemid 28108717)
10. Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol. 1998;16:864-871. (Pubitemid 28108718)
11. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20:4643-4648. (Pubitemid 36025280)
12. O'Neill BP, Wang CH, O'Fallon JR, et al. Primary central nervous system non-Hodgkin's lymphoma (PCNSL): survival advantages with combined initial therapy? A final report of the North Central Cancer treatment Group (NCCTG) Study 86-72-52. Int J Radiat Oncol Biol Phys. 1999;43:559-563.
13. Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Longterm follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24:4570-4574. (Pubitemid 46630953)
14. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organisation for Research and treatment of Cancer Lymphoma Group Phase II trial 20962. J Clin Oncol. 2003;21:4483-4488. (Pubitemid 46594017)
15. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034-5043.
16. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117-4126. (Pubitemid 46211317)
17. Nowakowski GS, Witzig TE. Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2006;4:225-231.
18. Doolittle ND, Jahnke K, Belanger R, et al. Potential of immunochemotherapy and radioimmunotherapy in relapsed primary CNS lymphoma. Leuk Lymphoma. 2007;48:1712-1720.
19. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology. 2004;63:901-903. (Pubitemid 39297656)
20. Wong Et, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer. 2004;101:139-145. (Pubitemid 38812433)
21. Neuwelt EA, Barnett P, McCormick CI, Remsen LG, Kroll RA, Sexton G. Differential permeability of a human brain tumor xenograft in the nude rat: the impact of tumor size and method of administration on optimizing delivery of biologically diverse agents. Clin Cancer Res. 1998;4:1549-1556. (Pubitemid 28265242)
22. Neuwelt EA, Barnett PA, Hellström KE, et al. Delivery of melanomaspecific immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res. 1988;48:4725-4729.
23. Soussain C, Muldoon LL, Varallyay C, Jahnke K, DePaula L, Neuwelt EA. Characterization and magnetic resonance imaging of a rat model of human B-cell central nervous system lymphoma. Clin Cancer Res. 2007;13:2504-2511. (Pubitemid 46698603)
24. Küker W, Nägele t, Korfel A, et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005;72:169-177.
25. Roman Goldstein SM, Goldman DL, Howieson J, Belkin R, Neuwelt EA. MR of primary CNS lymphoma in immunologically normal patients. AJNR Am J Neuroradiol. 1992;13:1207-1213.
26. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
27. Küker W, Nagele T, thiel E, Weller M, Herrlinger U. Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology. 2005;65:1129-1131.
28. Magrath IT, Freeman CB, Pizzo P, et al. Characterization of lymphomaderived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. II. Surface markers. J Natl Cancer Inst. 1980;64:477-483. (Pubitemid 10127261)
29. Fulci G, Breymann L, Gianni D, et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA. 2006;103:12873-12878. (Pubitemid 44298654)
30. Yamauchi K, Yang M, Hayashi K, et al. Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res. 2008;68:516-520.
31. Wu YJ, Muldoon LL, Dickey DT, Lewin SJ, Varallyay CG, Neuwelt EA. Cyclophosphamide enhances human tumor growth in nude rat xeno-grafted tumor models. Neoplasia. 2009;11(2): 187-195.
32. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol. 2006;24:1281-1288.
33. Blay JY, Bouhour D, Carrie C, et al. the C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood. 1995;86:2922-2929.
34. Herrlinger U, Schabet M, Brugger W, et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of singleagent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol. 2002;51:247-252. (Pubitemid 34111448)
35. Omuro AM, DeAngelis LM, Yahalom J, Abrey LE. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology. 2005;64:69-74. (Pubitemid 40082939)
36. Dukic SF, Heurtaux T, Kaltenbach ML, Hoizey G, Laliemand A, Vistelle R. Influence of schedule of administration on methotrexate penetration in brain tumours. Eur J Cancer. 2000;36:1578-1584. (Pubitemid 30619012)
37. O'Connor PM, Wassdermann K, Sarang M, Magrath I, Bohr VA, Kohn KW. Relationship between DNA cross-links, cell cycle, and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard. Cancer Res. 1991;51:6550-6557.
38. Iwamoto Y, Fujita Y, Sugioka Y. YIGSR, a synthetic laminin peptide, inhibits the enhancement by cyclophosphamide of experimental lung metastasis of human fibrosarcoma cells. Clin Exp Metastasis. 1992;10:183-189.
39. Barnett PA, Roman-Goldstein S, Ramsey F, et al. Differential permeability and quantitative MR imaging of a human lung carcinoma brain xenograft in the nude rat. Am J Pathol. 1995;146:436-449.
40. Neuwelt EA, Barnett PA, Hellström KE, Hellström I, McCormick CI, Ramsey FL. The effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral human carcinoma xenografts. J Nucl Med. 1994;35:1831-1841. (Pubitemid 24346809)
41. Kitzmann A, Pulido J, Mohney B, et al. Intraocular use of rituximab. Eye. 2007;12:1524-1527.
42. Ohguro N, Hashida N, tano Y. Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma. Arch Ophthalmol. 2008;126:1002-1003. (Pubitemid 352008390)
43. Angelov L, Doolittle ND, Kraemer DF, Siegal T, Barnett GH, Peereboom D, Stevens G, McGergor J, Jahnke K, Lacy CA, Hedrick NA, Shalom E, Ference S, Bell S, Sorenson L, Tyson RM, Haluska M, Neuwelt EA. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multiinstitutional study. J Clin Oncol. In press 2009.